ArticleClinicoEconomics and outcomes research : CEOR2013
The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.
Article in ClinicoEconomics and outcomes research : CEOR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Pooled it
- Feasibility and preliminary effectiveness of electronic medication monitoring system to improve antipsychotic adherence: a type 1 effectiveness-implementation hybrid pilot study.BMC psychiatry · 2026Trial
- The time toxicity experience of primary caregivers of schizophrenia: a descriptive phenomenological study.BMC nursing · 2025Article
- Gender-specific correlates for suicide mortality in people with schizophrenia: a 9-year population-based study.BMC psychiatry · 2024Article
- Cost-utility analysis of using paliperidone palmitate in schizophrenia in China.Frontiers in pharmacology · 2023Article
- The psychosis analysis in real-world on a cohort of large-scale patients with schizophrenia.BMC medical informatics and decision making · 2020Article
- The Views of Mental Health Manager Towards the Use of a Family Work Model for Psychosis in Guangzhou, China.Community mental health journal · 2018Article
- Quality of Life in Patients With a Major Mental Disorder in Singapore.Frontiers in psychiatry · 2018Article
- Direct medical costs for patients with schizophrenia: a 4-year cohort study from health insurance claims data in Guangzhou city, Southern China.International journal of mental health systems · 2018Article
- Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia.Nature genetics · 2017Article
- Prediction of Quality of Life in Asian Patients with Schizophrenia: A Cross-sectional Pilot Study.Frontiers in psychiatry · 2017Article
- Transition to Psychosis: Evaluation of the First-Degree Relatives of Patients with Schizophrenia .Iranian journal of psychiatry · 2016Article
- Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study.Neuropsychiatric disease and treatment · 2016Article
- The cost reduction in hospitalization associated with paliperidone palmitate in the People's Republic of China, Korea, and Malaysia.Neuropsychiatric disease and treatment · 2015Article
- Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan.ClinicoEconomics and outcomes research : CEOR · 2015Article
- Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.Neuropsychiatric disease and treatment · 2014Review
- Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China.Neuropsychiatric disease and treatment · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis article describes the personal, societal, and economic burden attributable to schizophrenia in the People's Republic of China and highlights the potential for effective outpatient treatment to reduce this burden given recent changes in the Chinese health care system. The importance of effective antipsychotic therapy in reducing the burden of schizophrenia is also examined.
methodsPublished research on the burden, disability, management, and economic costs of schizophrenia in the People's Republic of China was examined in the context of the larger body of global research. Research written in English or Chinese and published before June 2012 was identified using PubMed, CNKI, and Wanfang Med database searches. The contribution of effective antipsychotic therapy in reducing the risk for relapse and hospitalization and improving patients' functioning is described.
resultsSchizophrenia imposes a substantial burden on Chinese society, with indirect costs accounting for the majority of the total cost. Functional impairment is high, leading to lost wages and work impairment. In the People's Republic of China, schizophrenia is the most common diagnosis among hospitalized psychiatric patients. Ongoing changes in the Chinese health care system may reduce some barriers to effective relapse prevention in schizophrenia and potentially reduce hospitalizations. The use of antipsychotics for acute episodes and maintenance treatment has been shown to decrease symptom severity and reduce the risk for relapse and hospitalization. However, discontinuing antipsychotic medication appears common and is a strong predictor of relapse. Cost-effectiveness research in the People's Republic of China is needed to examine the potential gains from improved outpatient antipsychotic treatment.
conclusionSchizophrenia is a very costly mental illness in terms of personal, economic, and societal burden, both in the People's Republic of China and globally. When treated effectively, patients tend to persist longer with antipsychotic treatment, have fewer costly relapses, and have improved functioning. Further research examining the long-term effects of reducing barriers to effective treatments on the societal burden of schizophrenia in the People's Republic of China is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.